Overview

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Korea Ltd.
Treatments:
Ranibizumab